I am a breastfeeding mother and i want to know if it is safe to use UNII-1J444QC288? Is UNII-1J444QC288 safe for nursing mother and child? Does UNII-1J444QC288 extracts into breast milk? Does UNII-1J444QC288 has any long term or short term side effects on infants? Can UNII-1J444QC288 influence milk supply or can UNII-1J444QC288 decrease milk supply in lactating mothers?
- DrLact safety Score for UNII-1J444QC288 is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of UNII-1J444QC288 may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that UNII-1J444QC288 may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of UNII-1J444QC288 low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using UNII-1J444QC288 We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
It is excreted into breast milk in small amount (less than 10% of relative dose) without problems observed in infants whose mothers were on treatment with this drug. (Naito 2015, Ahn 2007)When measured, the plasma levels of drug in these infants were undetectable (Vasa 2013). Because its drug elimination period is very prolonged, an alternative drug known to be safer should be used, especially during the neonatal period and in case of premature infant.
Limited information indicates that milk levels of UNII-1J444QC288 are usually low and plasma levels in breastfed infants are undetectable. Maternal use of UNII-1J444QC288 during breastfeeding has not caused any adverse effects in breastfed infants. If UNII-1J444QC288 is required by the mother, it is not a reason to discontinue breastfeeding.
A woman took UNII-1J444QC288 for hypertension 5 mg daily beginning 2 weeks postpartum. Her exclusively breastfed infant was examined regularly and at 3 months of age was healthy and had normal physical and neurological development.[5] One woman received UNII-1J444QC288 2.5 mg orally twice daily during pregnancy for hypertension associated with glomerulonephritis. The dose was increased to 5 mg twice daily on day 2 postpartum. Her exclusively breastfed infant's growth was normal throughout the first year of life and no adverse effects were noted.[6] A preterm infant of 32 weeks gestation was breastfed exclusively from day 7 to day 20 postpartum. The infant's mother was taking UNII-1J444QC288 and labetalol in unspecified dosages for hypertension. The infant had apnea episodes unrelated to UNII-1J444QC288. Growth at 2 months of age was slightly low.[4] Thirty-one women with pregnancy-induced hypertension postpartum received UNII-1J444QC288 5 mg daily by mouth, with the dosage increased as needed to maintain blood pressure of 140/90 mm Hg or less. Their breastfed (extent not stated) infants exhibited no observed adverse cardiovascular effects within 3 weeks postpartum, although exact measurement methods were not stated.[1]
Disclaimer:
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.